1
|
Georgievski A, Bellaye PS, Tournier B, Choubley H, Pais de Barros JP, Herbst M, Béduneau A, Callier P, Collin B, Végran F, Ballerini P, Garrido C, Quéré R. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers. Cell Death Dis 2024; 15:328. [PMID: 38734740 DOI: 10.1038/s41419-024-06715-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 04/29/2024] [Accepted: 04/30/2024] [Indexed: 05/13/2024]
Abstract
We created valrubicin-loaded immunoliposomes (Val-ILs) using the antitumor prodrug valrubicin, a hydrophobic analog of daunorubicin. Being lipophilic, valrubicin readily incorporated Val-lLs that were loaded with specific antibodies. Val-ILs injected intravenously rapidly reached the bone marrow and spleen, indicating their potential to effectively target cancer cells in these areas. Following the transplantation of human pediatric B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), or acute myeloid leukemia (AML) in immunodeficient NSG mice, we generated patient-derived xenograft (PDX) models, which were treated with Val-ILs loaded with antibodies to target CD19, CD7 or CD33. Only a small amount of valrubicin incorporated into Val-ILs was needed to induce leukemia cell death in vivo, suggesting that this approach could be used to efficiently treat acute leukemia cells. We also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation, which is a significant advantage for clinical applications. Using EL4 lymphoma cells on immunocompetent C57BL/6 mice, we also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen, which could be valuable in impairing cancer cell expansion, particularly in lymphoma cases. The most efficient Val-ILs were found to be those loaded with CD11b or CD223 antibodies, which, respectively, target the myeloid-derived suppressor cells (MDSC) or the lymphocyte-activation gene 3 (LAG-3 or CD223) on T4 lymphocytes. This study provides a promising preclinical demonstration of the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of hematological cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.
Collapse
Affiliation(s)
- Aleksandra Georgievski
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- LipSTIC Labex, Dijon, France
| | - Pierre-Simon Bellaye
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- Plateforme d'imagerie et de radiothérapie précliniques, Centre Georges François Leclerc-Unicancer, Dijon, France
| | - Benjamin Tournier
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- Service de Pathologie, Plateforme de génétique somatique des cancers de Bourgogne, CHU Dijon-Bourgogne, Dijon, France
| | - Hélène Choubley
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- LipSTIC Labex, Dijon, France
- Plateforme DiviOmics, UMS58 Inserm BioSanD, Université de Bourgogne, Dijon, France
| | - Jean-Paul Pais de Barros
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- LipSTIC Labex, Dijon, France
- Plateforme DiviOmics, UMS58 Inserm BioSanD, Université de Bourgogne, Dijon, France
| | - Michaële Herbst
- Laboratoire Interdisciplinaire Carnot de Bourgogne, UMR6303 CNRS/Université de Bourgogne, Dijon, France
| | - Arnaud Béduneau
- LipSTIC Labex, Dijon, France
- Université de Franche-Comté, EFS, Inserm, UMR1098 RIGHT, Besançon, France
| | - Patrick Callier
- Laboratoire de Génétique Chromosomique et Moléculaire, CHU Dijon-Bourgogne, Dijon, France
| | - Bertrand Collin
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- Plateforme d'imagerie et de radiothérapie précliniques, Centre Georges François Leclerc-Unicancer, Dijon, France
| | - Frédérique Végran
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- LipSTIC Labex, Dijon, France
- Centre Georges François Leclerc-Unicancer, Dijon, France
| | - Paola Ballerini
- Laboratoire d'Hématologie, Assistance Publique-Hôpitaux de Paris, Hôpital Armand Trousseau, Paris, France
| | - Carmen Garrido
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France
- LipSTIC Labex, Dijon, France
- Centre Georges François Leclerc-Unicancer, Dijon, France
- Label of excellence from la Ligue Nationale contre le Cancer, Paris, France
| | - Ronan Quéré
- Center for Translational and Molecular Medicine, UMR1231 Inserm/Université de Bourgogne, Dijon, France.
- LipSTIC Labex, Dijon, France.
| |
Collapse
|
2
|
Godon J, Charles PE, Nguyen S, de Barros JPP, Choubley H, Jacquier M, Tetu J, Quenot JP, Luu M, Binquet C, Masson D, Piroth L, Blot M. Pneumococcal pneumonia and endotoxemia: An experimental and clinical reappraisal. Eur J Clin Invest 2024; 54:e14077. [PMID: 37642230 DOI: 10.1111/eci.14077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 07/20/2023] [Accepted: 08/02/2023] [Indexed: 08/31/2023]
Abstract
BACKGROUND Circulating endotoxins could result from bacterial digestive translocation during sepsis, thus contributing to uncontrolled systemic inflammation, leading in turn to organ dysfunction. We addressed this issue in the setting of severe pneumococcal pneumonia. METHODS Endotoxemia was measured in a clinically relevant rabbit model of ventilated pneumococcal pneumonia and in 110 patients with bacteraemic pneumonia, using a patented mass spectrometry (LC-MS/MS) method for detection of 3-OH fatty acids (C10, C12, C14, C16 and C18), which are molecules bound to the lipid A motif of LPS. RESULTS Whereas higher levels of systemic inflammation and organ dysfunctions were found, there was no significant difference in lipopolysaccharide concentrations when infected rabbits were compared to non-infected ones, or when patients were compared to healthy volunteers. CONCLUSIONS Seemingly, endotoxins do not drive the overwhelming inflammation associated with severe forms of pneumococcal pneumonia.
Collapse
Affiliation(s)
- Jeanne Godon
- Department of Infectious Diseases, Dijon-Bourgogne University Hospital, Dijon, France
| | - Pierre-Emmanuel Charles
- Department of Intensive Care, Dijon-Bourgogne University Hospital, Dijon, France
- Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France
| | - Sylvie Nguyen
- Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France
| | | | | | - Marine Jacquier
- Department of Intensive Care, Dijon-Bourgogne University Hospital, Dijon, France
- Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France
| | - Jennifer Tetu
- Laboratory of bacteriology, Dijon-Bourgogne University Hospital, Dijon, France
| | - Jean-Pierre Quenot
- Department of Intensive Care, Dijon-Bourgogne University Hospital, Dijon, France
- Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France
- CHU Dijon-Bourgogne, INSERM, Université de Bourgogne CIC 1432 Module Épidémiologie Clinique, Dijon France and LabEx LipSTIC, University of Burgundy, Dijon, France
| | - Maxime Luu
- CHU Dijon-Bourgogne, INSERM, Université de Bourgogne CIC 1432 Module Plurithématique, Dijon, University of Burgundy, Dijon, France
| | - Christine Binquet
- CHU Dijon-Bourgogne, INSERM, Université de Bourgogne CIC 1432 Module Épidémiologie Clinique, Dijon France and LabEx LipSTIC, University of Burgundy, Dijon, France
| | - David Masson
- Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France
| | - Lionel Piroth
- Department of Infectious Diseases, Dijon-Bourgogne University Hospital, Dijon, France
- CHU Dijon-Bourgogne, INSERM, Université de Bourgogne CIC 1432 Module Épidémiologie Clinique, Dijon France and LabEx LipSTIC, University of Burgundy, Dijon, France
| | - Mathieu Blot
- Department of Infectious Diseases, Dijon-Bourgogne University Hospital, Dijon, France
- Lipness Team, INSERM Research Centre LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France
- CHU Dijon-Bourgogne, INSERM, Université de Bourgogne CIC 1432 Module Épidémiologie Clinique, Dijon France and LabEx LipSTIC, University of Burgundy, Dijon, France
| |
Collapse
|
3
|
Lebrun LJ, Pallot G, Nguyen M, Tavernier A, Dusuel A, Pilot T, Deckert V, Dugail I, Le Guern N, Pais De Barros JP, Benkhaled A, Choubley H, Lagrost L, Masson D, Gautier T, Grober J. Increased Weight Gain and Insulin Resistance in HF-Fed PLTP Deficient Mice Is Related to Altered Inflammatory Response and Plasma Transport of Gut-Derived LPS. Int J Mol Sci 2022; 23:13226. [PMID: 36362012 PMCID: PMC9654699 DOI: 10.3390/ijms232113226] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/24/2022] [Accepted: 10/26/2022] [Indexed: 11/15/2023] Open
Abstract
Bacterial lipopolysaccharides (LPS, endotoxins) are found in high amounts in the gut lumen. LPS can cross the gut barrier and pass into the blood (endotoxemia), leading to low-grade inflammation, a common scheme in metabolic diseases. Phospholipid transfer protein (PLTP) can transfer circulating LPS to plasma lipoproteins, thereby promoting its detoxification. However, the impact of PLTP on the metabolic fate and biological effects of gut-derived LPS is unknown. This study aimed to investigate the influence of PLTP on low-grade inflammation, obesity and insulin resistance in relationship with LPS intestinal translocation and metabolic endotoxemia. Wild-type (WT) mice were compared with Pltp-deficient mice (Pltp-KO) after a 4-month high-fat (HF) diet or oral administration of labeled LPS. On a HF diet, Pltp-KO mice showed increased weight gain, adiposity, insulin resistance, lipid abnormalities and inflammation, together with a higher exposure to endotoxemia compared to WT mice. After oral administration of LPS, PLTP deficiency led to increased intestinal translocation and decreased association of LPS to lipoproteins, together with an altered catabolism of triglyceride-rich lipoproteins (TRL). Our results show that PLTP, by modulating the intestinal translocation of LPS and plasma processing of TRL-bound LPS, has a major impact on low-grade inflammation and the onset of diet-induced metabolic disorders.
Collapse
Affiliation(s)
- Lorène J. Lebrun
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Institut Agro Dijon, 1 Esplanade Erasme, 21000 Dijon, France
| | - Gaëtan Pallot
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Maxime Nguyen
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Department of Anesthesiology and Intensive Care, Dijon University Hospital, 21000 Dijon, France
| | - Annabelle Tavernier
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Institut Agro Dijon, 1 Esplanade Erasme, 21000 Dijon, France
| | - Alois Dusuel
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Thomas Pilot
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Valérie Deckert
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Isabelle Dugail
- Faculté de Médecine Pitié-Salpêtrière, UMR1269, 75000 Paris, France
| | - Naig Le Guern
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Jean-Paul Pais De Barros
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Lipidomic Analytic Plate-Forme, UBFC, Bâtiment B3, 21000 Dijon, France
| | - Anissa Benkhaled
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Hélène Choubley
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Lipidomic Analytic Plate-Forme, UBFC, Bâtiment B3, 21000 Dijon, France
| | - Laurent Lagrost
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - David Masson
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Laboratory of Clinical Chemistry, François Mitterrand University Hospital, 21000 Dijon, France
| | - Thomas Gautier
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Jacques Grober
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Institut Agro Dijon, 1 Esplanade Erasme, 21000 Dijon, France
| |
Collapse
|
4
|
Ménégaut L, Laubriet A, Crespy V, Nguyen M, Petit JM, Tarris G, Pilot T, Varin A, Choubley H, Bergas V, de Barros JPP, Thomas C, Steinmetz E, Masson D. Profiling of lipid mediators in atherosclerotic carotid plaques from type 2 diabetic and non-diabetic patients. Prostaglandins Leukot Essent Fatty Acids 2022; 184:102477. [PMID: 35952424 DOI: 10.1016/j.plefa.2022.102477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2021] [Revised: 07/18/2022] [Accepted: 08/03/2022] [Indexed: 12/29/2022]
Abstract
BACKGROUND AND AIMS Diabetes is associated with an accelerated development of atherosclerosis. Specific mechanisms related to diabetes and hyperglycemia may play a role in this process. In particular, alterations of arachidonic acid (AA) metabolism have been reported. Our main goal was to investigate for differences in the concentration of LTB4 and RvD1 as well as selected cyclooxygenase-derived mediators in carotid plaques from diabetic and non-diabetic patients. We also aimed to analyze the relationship between omega 6 and omega 3 Poly-Unsaturated Fatty acids (PUFAs) content in the plaques and the concentrations of these lipid mediators. METHODS 29 type 2 diabetic patients and 30 control patients admitted for surgical treatment of carotid stenosis were enrolled in the present study. Carotid plaques were harvested for in-depth lipidomic profiling. RESULTS No differences for LTB4 or other lipid mediators were observed between diabetic and non-diabetic patients. RvD1 levels were below the threshold of quantification in most of the samples. A significant correlation was found between LTB4 and 5(S)-HETE levels. Omega 3 enrichment was not significantly different between control and diabetic plaques. There was a negative correlation between DHA/AA ratio and the level of 5(S)-HETE while there was a positive association with TXB2 and PGD2 concentrations. CONCLUSION-PERSPECTIVES Our results does not support the hypothesis of a specific involvement of LTB4 or COX-derived mediators in diabetic atherosclerosis. The relationship between DHA enrichment and the concentrations of specific inflammatory mediators within the plaque is of interest and will need to be confirmed in larger studies.
Collapse
Affiliation(s)
- Louise Ménégaut
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France
| | - Aline Laubriet
- CHU Dijon, Department of Cardiovascular Surgery, Dijon, France
| | - Valentin Crespy
- CHU Dijon, Department of Cardiovascular Surgery, Dijon, France
| | - Maxime Nguyen
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon Department of Anesthesiology and Intensive Care, Dijon, France
| | - Jean-Michel Petit
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, Department of Endocrinology and metabolic diseases, Dijon, France
| | | | - Thomas Pilot
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Alexis Varin
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Hélène Choubley
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Victoria Bergas
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Jean-Paul Pais de Barros
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Lipidomic Analytic Platform, Université Bourgogne Franche-Comté, Dijon, France
| | - Charles Thomas
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Eric Steinmetz
- CHU Dijon, Department of Cardiovascular Surgery, Dijon, France
| | - David Masson
- Université Bourgogne Franche-Comté, LNC UMR1231, Dijon, France; INSERM, UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, Laboratory of Clinical Chemistry, Dijon, France.
| |
Collapse
|
5
|
Adda-Rezig H, Carron C, Pais de Barros JP, Choubley H, Charron É, Rérole AL, Laheurte C, Louvat P, Gaiffe É, Simula-Faivre D, Deckert V, Lagrost L, Saas P, Ducloux D, Bamoulid J. New Insights on End-Stage Renal Disease and Healthy Individual Gut Bacterial Translocation: Different Carbon Composition of Lipopolysaccharides and Different Impact on Monocyte Inflammatory Response. Front Immunol 2021; 12:658404. [PMID: 34163471 PMCID: PMC8215383 DOI: 10.3389/fimmu.2021.658404] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 05/18/2021] [Indexed: 12/12/2022] Open
Abstract
Chronic kidney disease induces disruption of the intestinal epithelial barrier, leading to gut bacterial translocation. Here, we appreciated bacterial translocation by analyzing circulating lipopolysaccharides (LPS) using two methods, one measuring only active free LPS, and the other quantifying total LPS as well as LPS lipid A carbon chain length. This was done in end-stage renal disease (ESRD) patients and healthy volunteers (HV). We observed both higher LPS concentration in healthy volunteers and significant differences in composition of translocated LPS based on lipid A carbon chain length. Lower LPS activity to mass ratio and higher concentration of high-density lipoproteins were found in HV, suggesting a better plasma capacity to neutralize LPS activity. Higher serum concentrations of soluble CD14 and pro-inflammatory cytokines in ESRD patients confirmed this hypothesis. To further explore whether chronic inflammation in ESRD patients could be more related to LPS composition rather than its quantity, we tested the effect of HV and patient sera on cytokine secretion in monocyte cultures. Sera with predominance of 14-carbon chain lipid A-LPS induced higher secretion of pro-inflammatory cytokines than those with predominance of 18-carbon chain lipid A-LPS. TLR4 or LPS antagonists decreased LPS-induced cytokine production by monocytes, demonstrating an LPS-specific effect. Thereby, septic inflammation observed in ESRD patients may be not related to higher bacterial translocation, but to reduced LPS neutralization capacity and differences in translocated LPS subtypes.
Collapse
Affiliation(s)
- Hanane Adda-Rezig
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France
| | - Clémence Carron
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France
| | | | - Hélène Choubley
- INSERM, Univ. Bourgogne Franche-Comté, LNC UMR1231, LabEx LipSTIC, Dijon, France
| | - Émilie Charron
- INSERM, Univ. Bourgogne Franche-Comté, LNC UMR1231, LabEx LipSTIC, Dijon, France
| | - Anne-Laure Rérole
- INSERM, Univ. Bourgogne Franche-Comté, LNC UMR1231, LabEx LipSTIC, Dijon, France
| | - Caroline Laheurte
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,EFS Bourgogne Franche-Comté, Plateforme de BioMonitoring, Besançon, France
| | - Pascale Louvat
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,EFS Bourgogne Franche-Comté, Plateforme de BioMonitoring, Besançon, France
| | - Émilie Gaiffe
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,INSERM CIC1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France
| | - Dominique Simula-Faivre
- University Hospital of Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France
| | - Valérie Deckert
- INSERM, Univ. Bourgogne Franche-Comté, LNC UMR1231, LabEx LipSTIC, Dijon, France
| | - Laurent Lagrost
- INSERM, Univ. Bourgogne Franche-Comté, LNC UMR1231, LabEx LipSTIC, Dijon, France
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,EFS Bourgogne Franche-Comté, Plateforme de BioMonitoring, Besançon, France.,INSERM CIC1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France
| | - Didier Ducloux
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,INSERM CIC1431, University Hospital of Besançon, Clinical Investigation Center in Biotherapy, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,University Hospital of Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France
| | - Jamal Bamoulid
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.,University Hospital of Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Besançon, France
| |
Collapse
|
6
|
Nguyen M, Bourredjem A, Piroth L, Bouhemad B, Jalil A, Pallot G, Le Guern N, Thomas C, Pilot T, Bergas V, Choubley H, Quenot JP, Charles PE, Lagrost L, Deckert V, de Barros JPP, Guinot PG, Masson D, Binquet C, Gautier T, Blot M. High plasma concentration of non-esterified polyunsaturated fatty acids is a specific feature of severe COVID-19 pneumonia. Sci Rep 2021; 11:10824. [PMID: 34031519 PMCID: PMC8144366 DOI: 10.1038/s41598-021-90362-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 05/04/2021] [Indexed: 12/15/2022] Open
Abstract
COVID-19 pneumonia has specific features and outcomes that suggests a unique immunopathogenesis. Severe forms of COVID-19 appear to be more frequent in obese patients, but an association with metabolic disorders is not established. Here, we focused on lipoprotein metabolism in patients hospitalized for severe pneumonia, depending on COVID-19 status. Thirty-four non-COVID-19 and 27 COVID-19 patients with severe pneumonia were enrolled. Most of them required intensive care. Plasma lipid levels, lipoprotein metabolism, and clinical and biological (including plasma cytokines) features were assessed. Despite similar initial metabolic comorbidities and respiratory severity, COVID-19 patients displayed a lower acute phase response but higher plasmatic concentrations of non-esterified fatty acids (NEFAs). NEFA profiling was characterised by higher level of polyunsaturated NEFAs (mainly linoleic and arachidonic acids) in COVID-19 patients. Multivariable analysis showed that among severe pneumonia, COVID-19-associated pneumonia was associated with higher NEFAs, lower apolipoprotein E and lower high-density lipoprotein cholesterol concentrations, independently of body mass index, sequential organ failure (SOFA) score, and C-reactive protein levels. NEFAs and PUFAs concentrations were negatively correlated with the number of ventilator-free days. Among hospitalized patients with severe pneumonia, COVID-19 is independently associated with higher NEFAs (mainly linoleic and arachidonic acids) and lower apolipoprotein E and HDL concentrations. These features might act as mediators in COVID-19 pathogenesis and emerge as new therapeutic targets. Further investigations are required to define the role of NEFAs in the pathogenesis and the dysregulated immune response associated with COVID-19.Trial registration: NCT04435223.
Collapse
Affiliation(s)
- Maxime Nguyen
- Department of Anesthesiology and Intensive Care, CHU Dijon and University of Burgundy, François Mitterrand University Hospital, LNC UMR1231, 21000, Dijon, France.
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France.
- INSERM, LNC UMR1231, 21000, Dijon, France.
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France.
| | - Abderrahmane Bourredjem
- Inserm, CIC1432, Clinical Epidemiology Unit, Clinical Epidemiology/Clinical Trial Unit, Dijon University Hospital, Dijon, France
| | - Lionel Piroth
- Inserm, CIC1432, Clinical Epidemiology Unit, Clinical Epidemiology/Clinical Trial Unit, Dijon University Hospital, Dijon, France
- Infectious Diseases Department, François Mitterrand University Hospital, Dijon, France
| | - Bélaïd Bouhemad
- Department of Anesthesiology and Intensive Care, CHU Dijon and University of Burgundy, François Mitterrand University Hospital, LNC UMR1231, 21000, Dijon, France
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
| | | | | | | | - Charles Thomas
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
| | | | - Victoria Bergas
- Lipidomic Analytic Platform, University of Burgundy, Dijon, France
| | - Hélène Choubley
- Lipidomic Analytic Platform, University of Burgundy, Dijon, France
| | - Jean-Pierre Quenot
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
- Inserm, CIC1432, Clinical Epidemiology Unit, Clinical Epidemiology/Clinical Trial Unit, Dijon University Hospital, Dijon, France
- Department of Intensive Care, François Mitterrand University Hospital, Dijon, France
| | - Pierre-Emmanuel Charles
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
- Inserm, CIC1432, Clinical Epidemiology Unit, Clinical Epidemiology/Clinical Trial Unit, Dijon University Hospital, Dijon, France
- Department of Intensive Care, François Mitterrand University Hospital, Dijon, France
| | - Laurent Lagrost
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
| | - Valerie Deckert
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
| | - Jean-Paul Pais de Barros
- INSERM, LNC UMR1231, 21000, Dijon, France
- Lipidomic Analytic Platform, University of Burgundy, Dijon, France
| | - Pierre-Grégoire Guinot
- Department of Anesthesiology and Intensive Care, CHU Dijon and University of Burgundy, François Mitterrand University Hospital, LNC UMR1231, 21000, Dijon, France
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
| | - David Masson
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
- Laboratory of Clinical Chemistry, François Mitterrand University Hospital, Dijon, France
| | - Christine Binquet
- Inserm, CIC1432, Clinical Epidemiology Unit, Clinical Epidemiology/Clinical Trial Unit, Dijon University Hospital, Dijon, France
| | - Thomas Gautier
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
| | - Mathieu Blot
- Univ. Bourgogne Franche-Comté, LNC UMR1231, 21000, Dijon, France
- INSERM, LNC UMR1231, 21000, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000, Dijon, France
- Infectious Diseases Department, François Mitterrand University Hospital, Dijon, France
| |
Collapse
|
7
|
Nguyen M, Pallot G, Jalil A, Tavernier A, Dusuel A, Le Guern N, Lagrost L, Pais de Barros JP, Choubley H, Bergas V, Guinot PG, Masson D, Bouhemad B, Gautier T. Intra-Abdominal Lipopolysaccharide Clearance and Inactivation in Peritonitis: Key Roles for Lipoproteins and the Phospholipid Transfer Protein. Front Immunol 2021; 12:622935. [PMID: 34054798 PMCID: PMC8149805 DOI: 10.3389/fimmu.2021.622935] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Accepted: 04/21/2021] [Indexed: 01/22/2023] Open
Abstract
Introduction During peritonitis, lipopolysaccharides (LPS) cross the peritoneum and pass through the liver before reaching the central compartment. The aim of the present study was to investigate the role of lipoproteins and phospholipid transfer protein (PLTP) in the early stages of LPS detoxification. Material and Methods Peritonitis was induced by intra-peritoneal injection of LPS in mice. We analyzed peritoneal fluid, portal and central blood. Lipoprotein fractions were obtained by ultracentrifugation and fast protein liquid chromatography. LPS concentration and activity were measured by liquid chromatography coupled with mass spectrometry and limulus amoebocyte lysate. Wild-type mice were compared to mice knocked out for PLTP. Results In mice expressing PLTP, LPS was able to bind to HDL in the peritoneal compartment, and this was maintained in plasma from portal and central blood. A hepatic first-pass effect of HDL-bound LPS was observed in wild-type mice. LPS binding to HDL resulted in an early arrival of inactive LPS in the central blood of wild-type mice. Conclusion PLTP promotes LPS peritoneal clearance and neutralization in a model of peritonitis. This mechanism involves the early binding of LPS to lipoproteins inside the peritoneal cavity, which promotes LPS translocation through the peritoneum and its uptake by the liver.
Collapse
Affiliation(s)
- Maxime Nguyen
- Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France
- Université Bourgogne Franche-Comté / Agrosup, Lipids Nutrition Cancer (LNC) UMR1231, Dijon, France
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Gaëtan Pallot
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Antoine Jalil
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Annabelle Tavernier
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Aloïs Dusuel
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Naig Le Guern
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Laurent Lagrost
- Université Bourgogne Franche-Comté / Agrosup, Lipids Nutrition Cancer (LNC) UMR1231, Dijon, France
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Jean-Paul Pais de Barros
- INSERM, LNC UMR1231, Dijon, France
- Lipidomic Analytical Platform, Université Bourgogne Franche-Comté (UBFC), Dijon, France
| | - Hélène Choubley
- INSERM, LNC UMR1231, Dijon, France
- Lipidomic Analytical Platform, Université Bourgogne Franche-Comté (UBFC), Dijon, France
| | - Victoria Bergas
- INSERM, LNC UMR1231, Dijon, France
- Lipidomic Analytical Platform, Université Bourgogne Franche-Comté (UBFC), Dijon, France
| | - Pierre-Grégoire Guinot
- Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France
- Université Bourgogne Franche-Comté / Agrosup, Lipids Nutrition Cancer (LNC) UMR1231, Dijon, France
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - David Masson
- Université Bourgogne Franche-Comté / Agrosup, Lipids Nutrition Cancer (LNC) UMR1231, Dijon, France
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
- Laboratory of Clinical Chemistry, François Mitterrand University Hospital, Dijon, France
| | - Belaid Bouhemad
- Department of Anesthesiology and Intensive Care, Dijon University Hospital, Dijon, France
- Université Bourgogne Franche-Comté / Agrosup, Lipids Nutrition Cancer (LNC) UMR1231, Dijon, France
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Thomas Gautier
- Université Bourgogne Franche-Comté / Agrosup, Lipids Nutrition Cancer (LNC) UMR1231, Dijon, France
- INSERM, LNC UMR1231, Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| |
Collapse
|
8
|
Bourgeois T, Jalil A, Thomas C, Magnani C, Le Guern N, Gautier T, Pais de Barros JP, Bergas V, Choubley H, Mazzeo L, Menegaut L, Josiane Lebrun L, Van Dongen K, Xolin M, Jourdan T, Buch C, Labbé J, Saas P, Lagrost L, Masson D, Grober J. Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet. J Lipid Res 2020; 62:100013. [PMID: 33518513 PMCID: PMC7859853 DOI: 10.1194/jlr.ra120000737] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2020] [Revised: 11/25/2020] [Accepted: 12/11/2020] [Indexed: 12/28/2022] Open
Abstract
Recent studies have highlighted an important role for lysophosphatidylcholine acyltransferase 3 (LPCAT3) in controlling the PUFA composition of cell membranes in the liver and intestine. In these organs, LPCAT3 critically supports cell-membrane-associated processes such as lipid absorption or lipoprotein secretion. However, the role of LPCAT3 in macrophages remains controversial. Here, we investigated LPCAT3's role in macrophages both in vitro and in vivo in mice with atherosclerosis and obesity. To accomplish this, we used the LysMCre strategy to develop a mouse model with conditional Lpcat3 deficiency in myeloid cells (Lpcat3KOMac). We observed that partial Lpcat3 deficiency (approximately 75% reduction) in macrophages alters the PUFA composition of all phospholipid (PL) subclasses, including phosphatidylinositols and phosphatidylserines. A reduced incorporation of C20 PUFAs (mainly arachidonic acid [AA]) into PLs was associated with a redistribution of these FAs toward other cellular lipids such as cholesteryl esters. Lpcat3 deficiency had no obvious impact on macrophage inflammatory response or endoplasmic reticulum (ER) stress; however, Lpcat3KOMac macrophages exhibited a reduction in cholesterol efflux in vitro. In vivo, myeloid Lpcat3 deficiency did not affect atherosclerosis development in LDL receptor deficient mouse (Ldlr-/-) mice. Lpcat3KOMac mice on a high-fat diet displayed a mild increase in hepatic steatosis associated with alterations in several liver metabolic pathways and in liver eicosanoid composition. We conclude that alterations in AA metabolism along with myeloid Lpcat3 deficiency may secondarily affect AA homeostasis in the whole liver, leading to metabolic disorders and triglyceride accumulation.
Collapse
Affiliation(s)
- Thibaut Bourgeois
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Antoine Jalil
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Charles Thomas
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Charlène Magnani
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Naig Le Guern
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Thomas Gautier
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Jean-Paul Pais de Barros
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; Lipidomic analytic plate-forme, Univ. Bourgogne Franche-Comté, Batiment B3, Bvd Maréchal de Lattre de Tassigny, Dijon, France
| | - Victoria Bergas
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; Lipidomic analytic plate-forme, Univ. Bourgogne Franche-Comté, Batiment B3, Bvd Maréchal de Lattre de Tassigny, Dijon, France
| | - Hélène Choubley
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; Lipidomic analytic plate-forme, Univ. Bourgogne Franche-Comté, Batiment B3, Bvd Maréchal de Lattre de Tassigny, Dijon, France
| | - Loïc Mazzeo
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Louise Menegaut
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Lorène Josiane Lebrun
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; AgroSup Dijon, Dijon, France
| | - Kévin Van Dongen
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Marion Xolin
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Tony Jourdan
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Chloé Buch
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Jérome Labbé
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte Greffon-Tumeur/Ingénierie Cellulaire et Génique, LabEx LipSTIC, Besançon, France
| | - Laurent Lagrost
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, laboratoire de Biochimie, Dijon, France
| | - David Masson
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; CHU Dijon, laboratoire de Biochimie, Dijon, France
| | - Jacques Grober
- Univ. Bourgogne Franche-Comté, LNC UMR12131, Dijon, France; INSERM, LNC UMR 1231, Dijon, France; FCS Bourgogne Franche-Comté, LipSTIC LabEx, Dijon, France; AgroSup Dijon, Dijon, France.
| |
Collapse
|
9
|
Dusuel A, Deckert V, Pais de Barros JP, van Dongen K, Choubley H, Charron É, Le Guern N, Labbé J, Mandard S, Grober J, Lagrost L, Gautier T. Human cholesteryl ester transfer protein lacks lipopolysaccharide transfer activity, but worsens inflammation and sepsis outcomes in mice. J Lipid Res 2020; 62:100011. [PMID: 33500240 PMCID: PMC7859855 DOI: 10.1194/jlr.ra120000704] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2020] [Revised: 11/25/2020] [Accepted: 12/09/2020] [Indexed: 02/06/2023] Open
Abstract
Bacterial lipopolysaccharides (LPSs or endotoxins) can bind most proteins of the lipid transfer/LPS-binding protein (LT/LBP) family in host organisms. The LPS-bound LT/LBP proteins then trigger either an LPS-induced proinflammatory cascade or LPS binding to lipoproteins that are involved in endotoxin inactivation and detoxification. Cholesteryl ester transfer protein (CETP) is an LT/LBP member, but its impact on LPS metabolism and sepsis outcome is unclear. Here, we performed fluorescent LPS transfer assays to assess the ability of CETP to bind and transfer LPS. The effects of intravenous (iv) infusion of purified LPS or polymicrobial infection (cecal ligation and puncture [CLP]) were compared in transgenic mice expressing human CETP and wild-type mice naturally having no CETP activity. CETP displayed no LPS transfer activity in vitro, but it tended to reduce biliary excretion of LPS in vivo. The CETP expression in mice was associated with significantly lower basal plasma lipid levels and with higher mortality rates in both models of endotoxemia and sepsis. Furthermore, CETPTg plasma modified cytokine production of macrophages in vitro. In conclusion, despite having no direct LPS binding and transfer property, human CETP worsens sepsis outcomes in mice by altering the protective effects of plasma lipoproteins against endotoxemia, inflammation, and infection.
Collapse
Affiliation(s)
- Aloïs Dusuel
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Valérie Deckert
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Jean-Paul Pais de Barros
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Kevin van Dongen
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Hélène Choubley
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Émilie Charron
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Naig Le Guern
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Jérôme Labbé
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Stéphane Mandard
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Jacques Grober
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France
| | - Laurent Lagrost
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France; University Hospital of Dijon, Dijon, France
| | - Thomas Gautier
- INSERM/University of Bourgogne Franche-Comté LNC UMR1231 and LipSTIC LabEx, UFR Sciences de Santé, Dijon, France.
| |
Collapse
|
10
|
Dargent A, Pais de Barros JP, Saheb S, Bittar R, Le Goff W, Carrié A, Gautier T, Fournel I, Rerole AL, Choubley H, Masson D, Lagrost L, Quenot JP. LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients. J Lipid Res 2020; 61:1776-1783. [PMID: 33037132 DOI: 10.1194/jlr.ra120001132] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Lipopolysaccharide (LPS) is a key player for innate immunity activation. It is therefore a prime target for sepsis treatment, as antibiotics are not sufficient to improve outcome during septic shock. An extracorporeal removal method by polymyxin (PMX) B direct hemoperfusion (PMX-DHP) is used in Japan, but recent trials failed to show a significant lowering of circulating LPS levels after PMX-DHP therapy. PMX-DHP has a direct effect on LPS molecules. However, LPS is not present in a free form in the circulation, as it is mainly carried by lipoproteins, including LDLs. Lipoproteins are critical for physiological LPS clearance, as LPSs are carried by LDLs to the liver for elimination. We hypothesized that LDL apheresis could be an alternate method for LPS removal. First, we demonstrated in vitro that LDL apheresis microbeads are almost as efficient as PMX beads to reduce LPS concentration in LPS-spiked human plasma, whereas it is not active in PBS. We found that PMX was also adsorbing lipoproteins, although less specifically. Then, we found that endogenous LPS of patients treated by LDL apheresis for familial hypercholesterolemia is also removed during their LDL apheresis sessions, with both electrostatic-based devices and filtration devices. Finally, LPS circulating in the plasma of septic shock and severe sepsis patients with gram-negative bacteremia was also removed in vitro by LDL adsorption. Overall, these results underline the importance of lipoproteins for LPS clearance, making them a prime target to study and treat endotoxemia-related conditions.
Collapse
Affiliation(s)
- Auguste Dargent
- Médecine Intensive Réanimation, Hôpital Edouard Herriot, Lyon, France; Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France.
| | - Jean-Paul Pais de Barros
- Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Samir Saheb
- Service d'endocrinologie et d'aphérèse, Hôpital Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Randa Bittar
- Service de Biochimie métabolique, Hôpital Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Wilfried Le Goff
- Sorbonne University, INSERM, Institute of Cardiometabolism and Nutrition (ICAN), UMR_S1166, Hôpital de la Pitié, Paris, France
| | - Alain Carrié
- Sorbonne University, INSERM, Institute of Cardiometabolism and Nutrition (ICAN), UMR_S1166, Hôpital de la Pitié, Paris, France; Hôpitaux Universitaires Pitié-Salpêtrière/Charles-Foix, Department of Biochemistry for Endocrinology and Oncology, Obesity and Dyslipidemia Genetics Unit, Paris, France
| | - Thomas Gautier
- Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Isabelle Fournel
- INSERM, CIC 1432, Module Epidémiologie Clinique, Dijon, France; CHU Dijon-Bourgogne, Centre d'Investigation Clinique, Module Epidémiologie Clinique/Essais Cliniques, Dijon, France
| | - Anne Laure Rerole
- Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - Hélène Choubley
- Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France
| | - David Masson
- Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Service de Biochimie médicale, CHU Dijon, Dijon, France
| | - Laurent Lagrost
- Université Bourgogne Franche-Comté, LNC, Dijon, France; INSERM, LNC UMR1231, Dijon, France; FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; Service de Biochimie médicale, CHU Dijon, Dijon, France
| | - Jean-Pierre Quenot
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, Dijon, France; INSERM, CIC 1432, Module Epidémiologie Clinique, Dijon, France; CHU Dijon-Bourgogne, Centre d'Investigation Clinique, Module Epidémiologie Clinique/Essais Cliniques, Dijon, France; Médecine Intensive Réanimation, CHU Dijon, Dijon, France
| |
Collapse
|
11
|
Dargent A, Pais De Barros JP, Ksiazek E, Fournel I, Dusuel A, Rerole AL, Choubley H, Masson D, Lagrost L, Quenot JP. Improved quantification of plasma lipopolysaccharide (LPS) burden in sepsis using 3-hydroxy myristate (3HM): a cohort study. Intensive Care Med 2019; 45:1678-1680. [DOI: 10.1007/s00134-019-05749-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2019] [Indexed: 01/22/2023]
|
12
|
Pais de Barros JP, Gautier T, Sali W, Adrie C, Choubley H, Charron E, Lalande C, Le Guern N, Deckert V, Monchi M, Quenot JP, Lagrost L. Quantitative lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus amebocyte lysate assay. J Lipid Res 2015; 56:1363-9. [PMID: 26023073 DOI: 10.1194/jlr.d059725] [Citation(s) in RCA: 79] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Indexed: 01/22/2023] Open
Abstract
Quantitation of plasma lipopolysaccharides (LPSs) might be used to document Gram-negative bacterial infection. In the present work, LPS-derived 3-hydroxymyristate was extracted from plasma samples with an organic solvent, separated by reversed phase HPLC, and quantitated by MS/MS. This mass assay was combined with the limulus amebocyte lysate (LAL) bioassay to monitor neutralization of LPS activity in biological samples. The described HPLC/MS/MS method is a reliable, practical, accurate, and sensitive tool to quantitate LPS. The combination of the LAL and HPLC/MS/MS analyses provided new evidence for the intrinsic capacity of plasma lipoproteins and phospholipid transfer protein to neutralize the activity of LPS. In a subset of patients with systemic inflammatory response syndrome, with documented infection but with a negative plasma LAL test, significant amounts of LPS were measured by the HPLC/MS/MS method. Patients with the highest plasma LPS concentration were more severely ill. HPLC/MS/MS is a relevant method to quantitate endotoxin in a sample, to assess the efficacy of LPS neutralization, and to evaluate the proinflammatory potential of LPS in vivo.
Collapse
Affiliation(s)
- Jean-Paul Pais de Barros
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Thomas Gautier
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Wahib Sali
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Christophe Adrie
- Physiology Department, Cochin Hospital, Paris University, Paris, France
| | - Hélène Choubley
- LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Emilie Charron
- LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Caroline Lalande
- LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Naig Le Guern
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Valérie Deckert
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Mehran Monchi
- Intensive Care Unit, Melun General Hospital, Melun, France
| | - Jean-Pierre Quenot
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France Intensive Care Unit University Hospital of Dijon, F-21000 Dijon, France
| | - Laurent Lagrost
- INSERM, LNC UMR866, F-21000 Dijon, France LNC UMR866, University Bourgogne Franche-Comté, F-21000 Dijon, France LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France Clinical Research Department, University Hospital of Dijon, F-21000 Dijon, France
| |
Collapse
|